At Marjan Pharmaceuticals, we are committed to delivering life-saving oncology medicines that meet international quality standards and align with the medical needs of the Gulf region and global cancer care. Our oncology portfolio covers a wide spectrum of cancer types — including breast, prostate, colorectal, lung, and blood cancers — providing physicians and patients with reliable, effective, and affordable options.
Our Oncology Range
Our registered oncology portfolio includes both oral and injectable formulations, ensuring comprehensive therapeutic coverage.Each product meets GMP-certified standards and is developed under strict WHO and PIC/S compliance, guaranteeing efficacy, safety, and accessibility.
Oral Oncology Medicines
Our oral formulations provide convenient and targeted therapies for outpatient and long-term management.Key products include:
- Imatinib – for Chronic Myeloid Leukemia (CML) and GIST
- Tamoxifen, Letrozole, Anastrozole – hormonal therapy for breast cancer
- Capecitabine – for breast, colorectal, and gastric cancers
- Abiraterone Acetate, Enzalutamide – for advanced prostate cancer
- Olaparib – a PARP inhibitor for ovarian and breast cancers
- Sunitinib, Sorafenib – for renal cell carcinoma and liver cancer
Injectable Oncology Medicines (IV)
Our IV formulations are designed for hospital and clinical use, offering precision treatment for various cancer types:- Cisplatin, Carboplatin, Oxaliplatin – platinum-based therapies for solid tumors
- Paclitaxel, Docetaxel – for breast, ovarian, and lung cancers
- Doxorubicin, Epirubicin – anthracycline-based chemotherapy
- Cyclophosphamide, Ifosfamide, Methotrexate (HD) – for lymphoma, leukemia, and osteosarcoma
- 5-Fluorouracil – for colorectal, gastric, and breast cancers
- Pemetrexed – for lung cancer
- Bevacizumab, Trastuzumab – targeted monoclonal antibody therapies (HER2+, colorectal, and breast cancer)